What is the role of amantadine in the management of Parkinson disease?

Amantadine in Parkinson's Disease: Roles and Evidence

Primary Indications and FDA Status

Amantadine is FDA-approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions, in addition to its original indication for influenza A prophylaxis and treatment. 1

The drug has demonstrated efficacy across multiple motor manifestations of Parkinson's disease through its unique dual mechanism combining dopaminergic and glutamatergic properties, along with anticholinergic and serotonergic effects 2.

Evidence-Based Clinical Roles

1. Treatment of Levodopa-Induced Dyskinesia (Strongest Evidence)

Amantadine is the first and only FDA-approved medication specifically for treating dyskinesia in Parkinson's disease, with the highest quality evidence supporting this indication. 3, 4

• Extended-release amantadine formulations are assessed as likely efficacious for motor fluctuations in the 2025 International Parkinson and Movement Disorder Society evidence-based review 4
• Extended-release amantadine reduces dyskinesia severity and duration during the day, decreases OFF time, and increases ON time without troublesome dyskinesia 3
• A 2025 meta-analysis found a standardized mean difference of -0.73 points for UPDRS/MDS-UPDRS Part IV at up to 16 weeks (P < 0.0001), representing the most substantial improvement among measured outcomes 5

Critical limitation: The magnitude of benefit decreases over time, indicating declining long-term efficacy beyond 16 weeks 5

2. Prevention of Dyskinesia in Early Parkinson's Disease (Emerging Evidence)

The 2025 PREMANDYSK trial provides the highest-quality recent evidence that early addition of amantadine to levodopa therapy halves the incidence of dyskinesia over 18 months. 6

• In early PD patients on stable levodopa (≥150 mg/day for ≤1 year) without motor complications, significantly fewer patients developed dyskinesia with amantadine versus placebo (11% vs 22%, P = 0.025) 6
• Amantadine reduced the mean daily levodopa dose increase by 70 mg (95% CI: 21-119 mg) compared to placebo (P = 0.005) 6
• Additional exploratory benefits included mild but significant positive effects on freezing of gait, fatigue, and quality of life 6

Important caveat: Long-lasting disease-modifying mechanisms could not be demonstrated in this trial 6

3. Symptomatic Treatment of Parkinsonian Motor Signs

• Amantadine is indicated for idiopathic Parkinson's disease, postencephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide intoxication or cerebral arteriosclerosis 1
• The drug is less effective than levodopa for motor symptoms, and its efficacy compared to anticholinergic antiparkinson drugs has not been fully established 1
• Amantadine has been used for over 50 years in symptomatic treatment, though it is now primarily utilized as add-on therapy rather than monotherapy 2, 7

4. Drug-Induced Extrapyramidal Reactions

• Amantadine is FDA-approved for treating drug-induced extrapyramidal reactions with a lower incidence of anticholinergic side effects compared to traditional anticholinergic antiparkinson drugs 1

5. Potential Role as Initial Monotherapy (Controversial)

A 2021 review suggests amantadine deserves reconsideration as initial treatment in early PD, though this remains outside mainstream practice. 7

• Amantadine has not been reported to cause dyskinesia and is rarely implicated in impulse control disorders, unlike dopamine agonists 7
• This potential role requires further investigation through controlled trials 2, 7

Critical Safety Considerations and Dosing

Mandatory Dose Reductions

All elderly patients (≥65 years) must receive a maximum daily dose of 100 mg (not the standard 200 mg) due to dose-dependent CNS toxicity, with elderly women at particularly high risk due to smaller body size. 8, 9

• Patients with creatinine clearance ≤50 mL/min/1.73m² require mandatory dose reduction because approximately 90% of amantadine is excreted unchanged in urine 8, 9
• Hemodialysis contributes minimally to amantadine clearance, so dosing adjustments based solely on dialysis are insufficient 8, 9

High-Risk Populations Requiring Close Monitoring

Patients with seizure disorders, psychiatric disorders, renal insufficiency, or elderly patients (especially women) have substantially elevated risk of serious CNS toxicity. 8, 9, 10

• An increased incidence of seizures has been reported in patients with seizure disorders receiving amantadine 8, 1
• Close observation is required during the first week of treatment for CNS toxicity (confusion, hallucinations, agitation) 9, 10

Adverse Event Profile

• At 200 mg/day, CNS side effects (nervousness, anxiety, insomnia, difficulty concentrating, lightheadedness) occur in approximately 13% of patients versus 4% with placebo 8, 9
• Serious CNS toxicity includes marked behavioral changes, delirium, hallucinations, agitation, and seizures, particularly when plasma concentrations are high 9, 1
• Gastrointestinal side effects (nausea, anorexia) occur in 1-3% of patients, comparable to placebo rates 9
• Most side effects are mild and resolve shortly after discontinuation or diminish after the first week despite continued use 9, 10

Contraindications and Warnings

• Amantadine is contraindicated in untreated angle-closure glaucoma due to its anticholinergic effects causing mydriasis 9, 1
• Deaths have been reported from overdose (lowest acute lethal dose: 1 gram) and from drug accumulation in patients with renal impairment prescribed higher than recommended doses 1
• Suicide attempts, some fatal, have been reported in patients treated with amantadine, including those without prior psychiatric history 1

Controversial Association with Impulse Control Disorders

A 2010 cross-sectional study found amantadine use positively associated with impulse control disorders (17.6% vs 12.4%, p < 0.001), contradicting earlier suggestions of therapeutic benefit. 11

• This association remained after controlling for dopamine agonist use and levodopa dosage 11
• The finding directly conflicts with the 2021 suggestion that amantadine is "rarely implicated" in impulse control disorders 7
• Further research, including larger clinical trials, is needed to clarify this relationship 11

Clinical Algorithm for Amantadine Use

For Established Dyskinesia:

1. Verify renal function (calculate creatinine clearance) before initiating 9
2. Start at 100 mg/day maximum for elderly patients (≥65 years); consider further reduction below 100 mg/day for elderly women or those with any renal impairment 9, 10
3. Monitor closely for CNS toxicity during the first week 9, 10
4. Expect peak benefit at 12-16 weeks, with declining efficacy thereafter 5
5. Reduce dose or discontinue immediately if serious side effects emerge 9, 10

For Early PD Without Dyskinesia:

1. Consider adding amantadine when initiating or escalating levodopa therapy to prevent dyskinesia development 6
2. Use standard dosing (200 mg/day for adults <65 years with normal renal function; 100 mg/day for elderly) 6
3. Monitor for exploratory benefits on freezing of gait and fatigue 6

Common Pitfalls to Avoid:

• Do not use standard 200 mg/day dosing in elderly patients – this substantially increases risk of serious CNS toxicity 8, 9, 10
• Do not ignore renal function assessment – failure to adjust for renal impairment has resulted in fatal drug accumulation 1
• Do not expect sustained long-term efficacy – evidence shows declining benefit beyond 16 weeks for dyskinesia 5
• Do not overlook psychiatric history – amantadine can exacerbate mental problems and has been associated with suicide attempts 1